In the published article, there was an error in the author list. In the published manuscript the author list appears erroneously: Cynthia Ménard¹*†, Inmaculada Navarro-Domenech²†, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung² on behalf of NIKE.
The corrected author list is as appears below.
Cynthia Ménard¹*†, Inmaculada Navarro-Domenech²†, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung²
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
prostate cancer, brachytherapy, salvage, radiotherapy, magnetic resonance imaging
Citation
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin M-C, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J and Chung P (2022) Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer. Front. Oncol. 12:1084708. doi: 10.3389/fonc.2022.1084708
Received
30 October 2022
Accepted
04 November 2022
Published
17 November 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2022
Updates
Copyright
© 2022 Ménard, Navarro-Domenech, Liu, Joseph, Barkati, Berlin, Delouya, Taussky, Beauchemin, Nicolas, Kadoury, Rink, Raman, Sundaramurthy, Weersink, Beliveau-Nadeau, Helou and Chung.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cynthia Ménard, Cynthia.Menard@umontreal.ca
†These authors have contributed equally to this work and share first authorship
This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.